ClinicalTrials.gg
Not yet recruitingNCT05911386Updated Aug 30, 2023

Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases

An observational study in Myocarditis, Pediatric Inflammatory Multisystem Syndrome and Kawasaki Disease, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Myocarditis with a site in France — 11 open to participants now, 13 under way, 2 of them phase 3. Myocarditis · France.

Planned enrollment
15th of 19
100 · median 500
Started
2023
with 2 others
Observational
19 of 31
8 open now
Primary completion
2023-09
later than 0 of 12 live
Registered
26th of 31
by date
Lead sponsor
3 of 31
Central Hospital, Nancy, France

Among the 31 studies in Myocarditis with a site in France, this one is the 15th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2023, is one of 19 observational ones, reaches primary completion later than 0 of the 12 other live ones, and was the 26th registered.

Myocarditis

175 studies on the registry are indexed under Myocarditis; 75 are open to participants now.

Browse Myocarditis studies →

Open to participants now

11 of the 31 studies in Myocarditis with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 53 Myocarditis studies recruiting now, 32 (60%) set no upper age limit and 6 (11%) stop at 75 or younger; 15 take children under 18; 14 take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Myocarditis with a site in France, or all of them as a file.
02

Study summary

Acquired inflammatory or infectious cardiac diseases, in pediatrics, include Kawasaki disease, myocarditis, and Covid-19-related Pediatric Multisystemic Inflammatory Syndrome (PIMS).

These 3 inflammatory cardiac diseases have clinical, biological, and echographic similarities and differences. Nevertheless their modalities of monitoring, management and evolution are different. The investigators wish to retrospectively analyze biological and echocardiographic data of Kawasaki disease, myocarditis, PIMS patients managed at Nancy Children Hospital from January 1, 2017 to June 31, 2023.

The primary objective of this study is to identify, for these 3 pathologies, the prognostic factors of initiation of inotropic support.

The secondary objective is to identify the prognostic factors of degradation of ventricular function.

03

Conditions studied

  • Myocarditis
  • Pediatric Inflammatory Multisystem Syndrome
  • Kawasaki Disease
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

age \< 18 years initial management and follow up in Nancy university children hospital center for PIMS Myocarditis and Kawasaki disease patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnostic of PIMS, myocarditis or kawasaki disease patients
  • age \< 18 years

Exclusion criteria

Exclusion Criteria:

  • uncertain diagnosis
  • other complex heart disease
  • management out of Nancy University children hospital center
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • MYOCARDITIS

    No intervention Study of available clinical, biological, and echocardiographic data

    Other: study of biological samples and echocardiographic data and link with need of hemodynamic support

  • KAWASAKI

    No intervention Study of available clinical, biological, and echocardiographic data

    Other: study of biological samples and echocardiographic data and link with need of hemodynamic support

  • PIMS

    No intervention Study of available clinical, biological, and echocardiographic data

    Other: study of biological samples and echocardiographic data and link with need of hemodynamic support

Interventions

  • Otherstudy of biological samples and echocardiographic data and link with need of hemodynamic support

    observational study : there is no intervention

06

What researchers measure

Primary outcomes

  1. need of hemodynamic support

    The need for haemodynamic support is defined dichotomously: yes or no. The investigators wish to identify the predictive factors of need for haemodynamic support among the following variables: groups (PIMS, KAWASAKI, MYOCARDITIS), cardiac biomarkers (troponin and NT-pro-BNP at admission (in ng/ml)) and echocardiographic criterias (Left Ventricular Ejection fraction, global and regional longitudinal strain at admission (in %)).

    Time frame: up to 20 days

Secondary outcomes

  1. deterioration of Left Ventricular Ejection fraction

    Left Ventricular Ejection fraction degradation is defined as an Left Ventricular Ejection fraction below the value of the first quartile of Left Ventricular Ejection fraction of all patients taken into account (Left Ventricular Ejection fraction as a percentage). The investigators wish to identify the predictive factors of Left Ventricular Ejection fraction degradation among the following variables: groups (PIMS, KAWASAKI, MYOCARDITIS), cardiac biomarkers (troponin and NT-pro-BNP at admission (in ng/ml)) and echocardiographic criterias (Left Ventricular Ejection fraction , global and regional longitudinal strain at admission (in %)).

    Time frame: up to 20 days

07

Study locations

1 site
  • Gilles BOSSER
    Vandœuvre-lès-Nancy, 54511, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2023; primary completion for Sep 2023, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
Jun 22, 2023
StartEst.
Sep 2023
Primary completionEst.
Sep 2023
CompletionEst.
Sep 2023
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05911386
Responsible party
BOSSER Gilles (chief of congenital and pediatric cardiology department, Central Hospital, Nancy, France) — Principal investigator
First posted
Jun 22, 2023
Start date
Sep 2023 (estimated)
Primary completion
Sep 2023 (estimated)
Completion
Sep 2023 (estimated)
Last update
Aug 30, 2023

Study contacts

Aurelien Capogna
Contact
a.capogna@chru-nancy.fr
+33603566308

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion